Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein

Palivizumab was the first antiviral monoclonal antibody (mAb) approved for therapeutic use in humans, and remains a prophylactic treatment for infants at risk for severe disease because of respiratory syncytial virus (RSV). Palivizumab is an engineered humanized version of a murine mAb targeting ant...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Proc Natl Acad Sci U S A
Main Authors: Mousa, Jarrod J., Sauer, Marion F., Sevy, Alexander M., Finn, Jessica A., Bates, John T., Alvarado, Gabriela, King, Hannah G., Loerinc, Leah B., Fong, Rachel H., Doranz, Benjamin J., Correia, Bruno E., Kalyuzhniy, Oleksandr, Wen, Xiaolin, Jardetzky, Theodore S., Schief, William R., Ohi, Melanie D., Meiler, Jens, Crowe, James E.
Format: Artigo
Sprog:Inglês
Udgivet: National Academy of Sciences 2016
Fag:
PNAS Plus
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5098655/
https://ncbi.nlm.nih.gov/pubmed/27791117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1609449113
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker